Advertisement
LLY vs MRK
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Merck (MRK) Stock Comparison
Key Takeaways
- LLY trades at a premium P/E (price-to-earnings) ratio of approximately 38x compared to MRK's 15x, highlighting differing growth expectations versus value positioning.
- Recent market activity shows LLY experiencing volatility with a year-to-date decline around 19%, while MRK holds positive year-to-date gains near 5-6%.
- LLY has pursued aggressive pipeline expansion through acquisitions like Ajax Therapeutics, bolstering oncology and hematology efforts.
- MRK demonstrates relative stability with strong one-year returns exceeding 38%, supported by Keytruda sales momentum.
- Both stocks face upcoming Q1 2026 earnings on April 30, with analysts projecting growth but varied sentiment based on sector catalysts.
- Analyst price targets suggest significant upside for LLY (around $1,200) versus moderate lift for MRK (near $130).
Introduction
Eli Lilly (LLY) and Merck (MRK) represent two pillars of the pharmaceutical sector, both leaders in innovative therapies amid evolving market dynamics. This stock comparison examines their recent performance, strategic moves, and relative positioning, aiding traders seeking short-term opportunities and long-term investors evaluating growth versus value trade-offs. With both companies reporting Q1 earnings soon, understanding their momentum, valuations, and catalysts provides clarity in a competitive healthcare landscape focused on oncology, obesity, and beyond.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY), a global biopharmaceutical firm, specializes in diabetes, obesity, oncology, and immunology treatments, with blockbuster drugs like Mounjaro and Zepbound driving revenue. In recent market activity, LLY shares have faced pressure, trading around $868 amid a year-to-date pullback of roughly 19% from 52-week highs near $1,134. This reflects broader sector rotation away from high-valuation growth names, compounded by profit-taking after earlier gains. Key influences include strategic acquisitions such as Ajax Therapeutics for up to $2.3 billion to strengthen hematology and partnerships like Profluent for AI-designed genetic medicines. Analysts remain bullish, with strong buy ratings and targets implying substantial upside, buoyed by obesity drug momentum including recent FDA approval for an oral GLP-1 candidate.
MRK Overview and Recent Performance
Merck & Co., Inc. (MRK), a diversified pharmaceutical giant, dominates in oncology with Keytruda, vaccines like Gardasil, and animal health. Shares hover near $110, with year-to-date gains around 5.5% and robust one-year returns over 38%, outperforming peers amid market volatility. Recent weeks show modest declines but relative resilience, supported by steady Keytruda demand and pipeline advancements. Developments include a tender offer for Terns Pharmaceuticals to enhance liver disease and cancer therapies, alongside health awareness campaigns on cardiovascular risks. Trading at a forward P/E of about 15x with a 52-week range of $73-$125, MRK benefits from defensive positioning and dividend appeal, with analysts forecasting moderate growth ahead of earnings.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from a library of over 350, handpicked by advanced algorithms for suitability in current market conditions like varying volatility levels. These bots employ diverse strategies—ranging from short-term signal generation (5-minute to 60-minute timeframes) to longer horizons—across stocks, ETFs, and crypto, using technical or fundamental analysis. Virtual and brokerage agents incorporate risk management, while signal agents offer real-time copy trading with no minimums. Performance highlights include adaptation to low, medium, or high volatility environments, enabling users to select bots matching their style. Explore these trending options to leverage AI-driven insights tailored to today’s dynamic markets.
Head-to-Head Comparison
LLY and MRK operate in overlapping pharma segments but diverge in business models: LLY emphasizes high-growth obesity and GLP-1 drugs, fueling premium valuations but higher volatility, while MRK relies on mature oncology blockbusters like Keytruda for steadier cash flows pre-patent cliffs. Growth drivers contrast sharply—LLY’s aggressive M&A (e.g., Ajax) versus MRK’s targeted acquisitions (e.g., Terns)—with recent momentum favoring MRK’s stability amid sector pressures. Risk factors include LLY’s elevated P/E exposure to competition and MRK’s Keytruda exclusivity risks post-2028. Market sentiment leans toward LLY for upside potential but MRK for relative value in defensive positioning.
Tickeron AI Verdict
Tickeron’s AI analysis leans toward LLY in the current environment, driven by consistent pipeline catalysts like recent acquisitions and superior analyst upside projections amid obesity drug tailwinds. While MRK offers stability and attractive valuation, LLY’s trend positioning and growth probability edge it ahead probabilistically, though both warrant monitoring post-earnings for shifts in relative strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- LLY’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 3 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s).
- LLY’s TA Score: 3 bullish, 5 bearish.
- MRK’s TA Score: 5 bullish, 5 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а -1.37% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.27%. For the same industry, the average monthly price growth was +6.74%, and the average quarterly price growth was +3.04%.
Reported Earning Dates
LLY is expected to report earnings on Aug 05, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.27% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| LLY | MRK | LLY / MRK | |
| Capitalization | 987B | 295B | 335% |
| EBITDA | 36.2B | 19.4B | 187% |
| Gain YTD | 3.364 | 11.317 | 30% |
| P/E Ratio | 39.15 | 32.53 | 120% |
| Revenue | 72.2B | 65.8B | 110% |
| Total Cash | 5.28B | N/A | - |
| Total Debt | 43.4B | 49.1B | 88% |
LLY | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 50 | |
SMR RATING 1..100 | 12 | 47 | |
PRICE GROWTH RATING 1..100 | 23 | 30 | |
P/E GROWTH RATING 1..100 | 86 | 6 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as LLY (20). This means that MRK’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (50). This means that LLY’s stock grew somewhat faster than MRK’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (47). This means that LLY’s stock grew somewhat faster than MRK’s over the last 12 months.
LLY's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as MRK (30). This means that LLY’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for LLY (86). This means that MRK’s stock grew significantly faster than LLY’s over the last 12 months.
| LLY | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | 2 days ago 49% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 48% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 68% | 2 days ago 53% |
| Advances ODDS (%) | 16 days ago 69% | 7 days ago 54% |
| Declines ODDS (%) | 6 days ago 56% | 9 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 49% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 64% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.